PITTSBURGH — Mylan Inc. has launched norethindrone tablets 0.35 mg, a birth control pill.
The company reported Tuesday that its partner, Famy Care Ltd., received final approval from the Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for the product.
product Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched
Mylan said its norethindrone tablets are a generic version of Watson Laboratories’ (now Actavis Inc.) Nor-Q.D. Tablets 0.35 mg (28-Day Cycle), which are indicated for the prevention of pregnancy.
Norethindrone tablets 0.35 mg had U.S. sales of about $39 million for the 12 months ended March 31, according to IMS Health figures cited by Mylan.
